Skip to main content Skip to Footer
June 29, 2015
Highlights from BIO International: New patient care management approaches
By: Jeff Elton Ph.D.

Challenging industry-leading companies to develop patient care management models that improve patient outcomes. 

This past week, from June 15-18, I had the great pleasure of attending the Bio International Convention in Philadelphia, PA. This annual convention attracts more than 2,500 CEOs and 15,000 global life sciences attendees from all aspects of the industry—from drug discovery, biomanufacturing, genomics, biofuels, nanotechnology and cell therapy. Featuring keynotes, super sessions, education tracks and networking events, the convention offers a range of opportunities for attendees to learn from and connect with industry executives.

One of the highlights of the event for me was moderating the panel How We Heal: New Patient Care Management Approaches. Our panel included:

  • Anil Jain, M.D., Co-Founder and Chief Medical Officer, Watson Health/Explorys
  • Jesus Leal, SVP Marketing, BD&L and Strategy, Novartis US
  • Tom Tsang M.D., Chief Medical Officer, Health Services & Solutions, Merck & Co.  

During the panel we discussed how the life sciences industry is moving toward a value-centric model and where the catalyst for this transformation comes from, including:

  • Wholesale shifts in reimbursement emphasizing population health, clinical outcomes, and value to the health system.
  • Collaborative working models that challenge traditional definitions of the ‘health provider’ and ‘risk bearer’.
  • The opportunity and responsibility to leverage the wealth of real world data available to payers, providers and increasingly life science companies.

Those with transformative therapeutics that hold the potential of improving patient outcomes will need access to real-world data to support that model and direct effort towards complementary investments that assure patients are the sole beneficiaries. These new biopharma commercial models will focus on the effective management of patient care aligned with the goals of risk-bearing providers or single-payers. Pharma companies are exploring sustainable business models that are “around the patient”, increasingly collaborative with a variety of healthcare organizations for integrated patient care management. Underlying all of these approaches is real-world data, advanced analytics and insights into current coordinated care failures and possible remedies. These same data and analytics are supporting these new care management models and value-based pricing or reimbursement.

Our panelists explored how this change is challenging industry-leading companies to develop new patient care management approaches, collaborations and whole new business entities. The early initiatives here are being met positively by payers and risk-bearing providers for their positive impact on the industry, HCPs and most importantly, patients.

Once again this convention was a wonderful opportunity to connect with attendees from around the world. I’d like to express my thanks to Biotechnology Industry Organization for hosting and organizing a world-class event.

If you’d like to talk with me about the new patient care management approaches, please don’t hesitate to reach out.

To learn more about the Bio International Convention or find out about next year’s event, visit the convention website.

More blogs on this topic